Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pharma News for Actinium, Santhera, Gilead, Seres, BMS, Boehringer

Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an antibody armed with a radioisotope designed to deliver targeted treatment to tumors while sparing healthy tissues, was completed on 31 October 2022, according to the company. SIERRA enrolled 150 patients with relapsed or refractory AML who were randomly assigned to either Iomab-B or standard therapy as a conditioning regimen before transplant. According to Ac...

Explore More...

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos

InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

recent-pharma-happenings-for-eli-lilly-mina-appia-bio-nuvalent

Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids

Pfizer/BioNTech COVID-19 Vaccine; Biogen/Capsigen Deal

Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

recent-pharma-happenings-for-pfizer-abcellera-sarepta-eli-lilly

Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic

MedTech Industry Roars Back as FDA Approvals Soar

recent-pharma-biotech-news-updates-happenings-for-abbott-biogen-eli-lilly-arch-oncology

Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med

recent-pharma-biotech-lifescience-healthcare-news-updates-for-vertex-virta-kalvista-ovid-crispr-therapeutics

Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa

Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

recent-pharma-happenings-for-recursion-repertoire-cequr-eli-lilly

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

recent-pharma-news-and-updates-for-astrazeneca-sanofi-taysha

Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

recent-pharma-news-updates-for-artios-scholar-rock-novavax-volastra

Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain

Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

recent-pharma-news-update-happenings-for-amgen-rodeo-novartis-organon-alydia-forma

Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Latest-biotech-pharma-news-updates-for-ajinomot-pfizer-ikena-lilly-bright-peak

Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer’s Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing

recent-pharma-happenings-for-asher-bio-roche-novartis-epimab

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids

Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic

MedTech Industry Roars Back as FDA Approvals Soar

Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med

Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy

More Views & Analysis

Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M

Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer’s Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing

Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche’s Tecentriq Results in NSCLC

Subscribe to our Updates

Daily

Weekly

Monthly